

### Levodopa/carbidopa

S

#### Hallucinations: case report

A 67-year-old man developed hallucinations during treatment with levodopa/carbidopa for parkinsonism.

The man was referred to movement disorders centers 4 months after the COVID-19 pandemic got started in Iran. In March 2020, he had several episodes of falls, dry mouth and skin, tachycardia and constipation. Later, bradykinesia was added to his symptoms. He was suspected to have parkinsonism and started receiving levodopa/carbidopa 600/150mg [*route not stated*]; however, levodopa/carbidopa caused hallucination [*duration of treatment to reaction onset not stated*].

Hence, the man discontinued levodopa/carbidopa [*outcome not stated*]. At the same time, his systemic evaluation, chest CT and SARS-CoV-2 PCR were negative. He only had mild bilateral action tremor on his hands, severe rigidity on limbs, severe generalized bradykinesia, and he could not walk without support. At the time of current presentation, brain MRI including DWI sequence did not show any abnormalities, and routine laboratory tests came back negative. He started receiving levodopa/benserazide, which led to mark improvement in his condition. However, a repeat brain MRI did not show any change from the previous one. After four months due to malaise, SARS-CoV-2 PCR has been checked and was positive; therefore, he took conservative management at home and recovered. He did not experience anosmia or respiratory symptoms; however, his parkinsonism got worsened later. Unfortunately, after two months in January 2021, he had a cardiac arrest and died of it.